What does Pharming do?
Pharming develops innovative products for the safe, effective treatment of rare diseases and unmet medical needs. We are specialists in the production of protein therapeutics. Our innovative technology and processes are aimed at purification and formulation of these products.
Hereditary Angioedema (HAE) is a rare genetic condition which occurs in approximately 1 in 30,000 people worldwide. Symptoms include episodes of swelling in the hands, feet, abdomen, face and airway. Patients may suffer bouts of excruciating abdominal pain, nausea and vomiting that is exacerbated by swelling in the intestinal wall. Airway (laryngeal) swelling is particularly dangerous and can lead to death by asphyxiation.
C1 inhibitor is normally found in our blood.  Patients with HAE, however, have low levels of functioning C1 inhibitor.  There are many triggers for an attack including stress, medications, trauma, hormone changes etc.  An attack begins with the activation of (FXII and Kallikrein) that are normally kept in check by C1 inhibitor (C1-INH).  Eventually, because there is not enough C1-INH available, this activation leads to the production of bradykinin, which leads to fluid leaking out of the blood vessels and into the tissues (angioedema).
Recombinant technology is a state of the art, efficient way to produce complex human proteins such as C1-INH without the need for human plasma donations. This technology has been used for more than 30 years to make medicines that treat a wide variety of conditions such as asthma, diabetes, hemophilia, and cancer.  
RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in the US, Israel, all 28 EU countries plus Norway, Iceland, and Liechtenstein.
RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor (rhC1INH). C1 esterase inhibitor (C1INH) is a protein that naturally occurs in the human body. It belongs to the class of serine-protease inhibitors or serpins. It regulates several inflammatory pathways in the body by inhibiting certain proteins (proteases) that are part of the human immune system. Deficiency of functional C1 inhibitor leads to excessive activation of the complement system and other immunological and hemostatic pathways, giving cause to angioedema attacks.


Where is Pharming's corporate headquarters?
Pharming Group N.V.
Darwinweg 24
2333 CR Leiden
The Netherlands
Pharming’s shares are listed on EURONEXT Amsterdam since 1999 and has ADS’s listed on Nasdaq Global Market as of 22 December 2020.

Pharming’s shares are listed on EURONEXT Amsterdam under the symbol “PHARM’’, since 1999. The shares (ISIN Code: NL0010391025) are traded through the book-entry facilities of Euroclear Nederland.

Pharming has ADS’s listed on Nasdaq Global Market under the symbol “PHAR” as of 22 December 2020. Each ADS (ISIN Code: US71716E1055) is a tradeable security representing 10 Ordinary Shares.

Company Inquiries

How many employees does Pharming have?
Pharming currently has over 260 employees.

You can find all information about Pharming via www.pharming.com
Should you have any questions, please contact investor@pharming.com

To learn more about our Executive Committee and our Board of Directors please click here.
Should you have any further questions please don’t hesitate to contact us at investor@pharming.com 
Please sign up to our distribution list on our website to receive our press releases in your inbox: www.pharming.com/contact

A: The following analysts track Pharming:
Oppenheimer & Co. Inc.
H.C. Wainwright
Stifel Financial Corp.
First Berlin Research
ROTH Capital Partners
Kempen Healthcare
Degroof Petercam